Advagraf®

Advagraf®

tacrolimus extended release capsules

0.5 mg, 1 mg, 3 mg and 5 mg capsules

Immunosuppressant

INDICATIONS AND CLINICAL USE
Advagraf (tacrolimus extended release capsules) is indicated for prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants.

Advagraf is to be used concomitantly with adrenal corticosteroids and mycophenolate mofetil (MMF) in de novo renal transplant recipients. Antibody induction therapy should also be used in kidney transplant recipients.

Stable renal transplant patients may be converted from Prograf (twice daily) to Advagraf (once daily), in combination with adrenal corticosteroids and MMF, based on equivalent tacrolimus blood concentrations. Any changes in immunosuppressive therapy must be initiated by physicians experienced in immunosuppressive therapy and the management of transplant patients.

Pediatrics (< 18 years of age): Experience with Advagraf in pediatric kidney transplant
patients is limited.

Geriatrics (≥ 65 years of age): Experience with Advagraf in patients older than 65 years of age is limited.

CONTRAINDICATIONS

Advagraf (tacrolimus extended release capsules) is contraindicated in patients with hypersensitivity to tacrolimus or to any ingredient in the formulation or component of the capsules. For please click here complete information.